Showing results (351-360 of 384) with videos related to

Sort By:
Pageof 39
Cancers|April 3, 2021
Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II StudyChristine H Chung, Marcelo Bonomi, Conor E Steuer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2013
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studiesDong M Shin, Hongzheng Zhang, Nabil F Saba, et al.
Nature Communications|February 12, 2025
DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107Matthew P Morrow, Elisabeth Gillespie, Albert Sylvester, et al.
Heart Rhythm O2|November 30, 2023
Association of pre-left ventricular assist device defibrillator shocks for ventricular arrhythmia with clinical outcomes after left ventricular assist device implantationDaniel G Wann, Andrew S Baird, Norman C Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2021
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS MutationsAlan L Ho, Irene Brana, Robert Haddad, et al.
American Journal of Clinical Oncology|September 4, 2025
Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical TrialRobin Park, Fahad Rind, Tyler Kristoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaChristine H Chung, Jiannong Li, Conor E Steuer, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 3, 2013
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic studyNabil F Saba, Selwyn J Hurwitz, Scott A Kono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2024
Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker AnalysisNabil F Saba, Ritu Chaudhary, Kedar Kirtane, et al.
JCO Oncology Practice|July 21, 2026
Tobacco Use and Cessation Patterns Among Cancer Survivors: Results From Nine ECOG-ACRIN Cancer Research Group TrialsRachel L Rosen, Ju-Whei Lee, Ilana F Gareen, et al.
Pageof 39